Sofosbuvir
Hepatitis C Induced Liver Cirrhosis
Explore 3 assets in Hepatitis C Induced Liver Cirrhosis →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Institute of Liver and Biliary Sciences, India
Modality
Small molecule
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02464631CT.gov To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Induced Liver Cirrhosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sofosbuvir (this asset) | Institute of Liver and Biliary Sciences, India | N/A | D · 30 |
| Umbellatine | Tianjin Second People's Hospital | P3 | B |
| Carvedilol | Tianjin Second People's Hospital | P3 | B |
| Rosuvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | CCC |
| Ribavirin | Institute of Liver and Biliary Sciences, India | N/A | D |
| Foscenvivint | Komagome Hospital | P1 | NR |
Other indications for Sofosbuvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P4 | A · 82 |
| Chronic Hepatitis C Virus Infection | — | P4 | A · 81 |
| Cirrhosis Of Liver | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sofosbuvir in Hepatitis C Induced Liver Cirrhosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sofosbuvir-hepatitis-c-induced-liver-cirrhosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →